Patent ID: 9731001
Date: 2017-08-15
CPC Classifications: A61K,A61P,C07C,C07D,C07K,G16B,G16C

Claim:
1. A method of reducing a human immunodeficiency virus type-1 (HIV-1) infection and/or HIV-1 propagation in a subject, comprising: administering to said subject a therapeutically effective amount of a compound which binds with a dendritic cell immunoreceptor (DCIR) (SEQ ID NO: 1) on a first or on a second three-dimensional cavity, wherein: the first three-dimensional cavity of DCIR comprises residues Phe113, Asn116, Tyr118, Val143, Ile144, Trp178 and Glu231; and the second three-dimensional cavity of DCIR comprises residues Arg194, Glu195, Pro196, Ser197, Asp198, His175, Trp176 and Glu201; and wherein said compound decreases human immunodeficiency virus type-1 (HIV-1) production and/or attachment in a dendritic cell or a CD4 + T cell.